Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in September 2008 on request of the sponsor.
On 29 December 2000, orphan designation (EU/3/00/009) was granted by the European Commission to Laboratoires LAPHAL, France, for thalidomide for the treatment of erythema nodosum leprosum (ENL) or type II lepra reactions.
The sponsorship was transferred to Laphal Developpement, France, in November 2002. Laphal Developpement changed name to Pharmion Developpement in July 2004 and subsequently to Pharmion France in November 2007.
Treatment of erythema nodosum leprosum (ENL) or type II lepra reactions
|Orphan designation status||
|EU designation number||
|Date of designation||
6/8 Boulevard Haussmann
Telephone : +33 1 42 99 97 02
Telefax : +33 1 42 99 97 01
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: